DM
SNDX icon

Deerfield Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Deerfield Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.6M Hold
3,779,900
– – 0.86% 34
2026
Q1 		$88.3M Buy
+3,779,900
New +$82.1M 1.04% 28
2022
Q3 		– Sell
-1,111,111
Closed -$21.4M – 136
2022
Q2 		$21.4M Buy
+1,111,111
New +$18.5M 0.44% 59
2017
Q2 		– Sell
-38,130
Closed -$523K – 94
2017
Q1 		$523K Buy
+38,130
New +$396K 0.02% 105

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Deerfield Management's SNDX Position: Q2 2026 in Review

Deerfield Management held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 3,779,900 shares worth $82.6M. The position accounts for 0.86% of the portfolio, ranked #34.

Deerfield Management first reported a position in SNDX in Q1 2017 and has held it in 4 quarters since. The position peaked at $88.3M in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Deerfield Management held 3,779,900 shares of Syndax Pharmaceuticals worth $82.6M as of Q2 2026.
  • Deerfield Management left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
  • Syndax Pharmaceuticals made up 0.86% of Deerfield Management's portfolio in Q2 2026, its #34 holding.
  • Deerfield Management first reported a position in Syndax Pharmaceuticals in Q1 2017 and has held it in 4 quarters since.
  • Deerfield Management's Syndax Pharmaceuticals position peaked at $88.3M in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.